Head and Neck Squamous Cell Carcinoma (HNSCC) research hub
8 indexed studies · 3 currently recruiting
- recruitingPHASE1, PHASE2
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
This study is looking at a new drug, GTAEXS617, for people with advanced solid tumours, including certain types of breast, lung, head and neck, and ovarian cancers. We want to see how safe it is, how the body handles it, and if it can shrink tumours.
United States · Belgium · United Kingdom - authorisedPhase I and Phase II (Integrated)- First administration to humans
[18F]-olaparib PET; Molecular imaging of DNA damage response by [18F]-olaparib PET
This study looks at a new way to scan for head and neck cancer using a special dye called [18F]-olaparib. It aims to see how this dye lights up cancer cells compared to healthy cells, helping doctors understand if it can improve how we detect and treat this type of cancer.
Netherlands - active not recruitingPHASE1, PHASE2
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
This study is testing a new cancer medicine, GEN1042, both by itself and with other treatments. It's for people with certain advanced solid tumours where standard treatments haven't worked or aren't available. The main goals are to check its safety and see how well it fights cancer.
United States · Denmark · France - recruitingPHASE1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
This study is testing a new drug, zanzalintinib, alone and with other medicines, for people with advanced cancers like kidney, prostate, and lung cancer. It's looking at safety and if the treatment shrinks tumours.
United States · Australia · Austria - active not recruitingPHASE1
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
This study looks at new ways to treat head and neck cancer. It combines different medicines that help your immune system fight cancer and stop tumours from growing. It's for people whose previous treatments weren't successful or who don't have standard options.
United States · France · Japan - active not recruitingPHASE2, PHASE3
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
This study is looking at a new treatment for advanced head and neck cancer. It combines two medicines, INBRX-106 and pembrolizumab, to see if they work better together than pembrolizumab alone. It's for people whose cancer can't be cured by other methods.
United States · Australia · Belgium - recruitingNA
Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Cell Carcinoma (HNSCC)
This study looks at whether checking on symptoms remotely, using a digital tool, can help head and neck cancer patients. The main goal is to see if this kind of monitoring can reduce weight loss after treatment by catching problems early and offering better support.
France - active not recruitingPHASE2
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
This study looks at a new way to treat recurrent or new head and neck cancer. We are testing if adding a drug called pembrolizumab to targeted radiation therapy (SBRT) can help stop the cancer from growing. This is a Phase 2 study.
United States · Canada